Agilent Technologies Announces Early Access to Custom guideRNA for Functional Genomics
News Feb 13, 2016
Agilent Technologies Inc. has announced a program that gives biologists conducting functional genomics research early access to a potential new resource: custom CRISPR guideRNA libraries using Agilent’s high-quality oligo library synthesis platform.
Agilent announced the early access program at a technology conference—Advances in Genome Biology and Technology (AGBT)—which continues through Friday in Orlando, Florida.
The custom Sure Guide gRNA libraries will complement Agilent’s Sure Guide Cas9 nuclease kit, when available for commercial release. Both will be part of an integrated solution for research involving clustered regularly interspaced short palindromic repeats (known as CRISPR systems) and associated genes.
Researchers are excited about CRISPR-Cas9 gene-editing technology because it enables scientists doing large-scale, functional genomics screens to investigate the role of genetic mutations in human disease. With CRISPR libraries, researchers have access to the first system that can fully remove the function of genes at the DNA level, compared with other tools like RNA interference that suppress gene expression at the RNA level.
“We are pleased to provide researchers with early access to custom Sure Guide gRNA for evaluation,” said Alessandro Borsatti, the head of product marketing for Agilent’s Diagnostics and Genomics Group. “This program will accelerate the ability of researchers to identify critical sequences responsible for a gene’s functional properties and enable them to perform targeted genome editing with unprecedented ease.”
Scientists who would like to take part in the early access program and provide feedback to Agilent can sign up at www.agilent.com/genomics/CRISPREA.
At AGBT on Feb. 12, Israel Steinfeld, a scientist from Agilent Labs, will deliver a presentation titled “Improved Methods and Analysis Tools for Efficient CRISPR/Cas Genome Editing.”
Mechanism Controlling Multiple Sclerosis Risk IdentifiedNews
Researchers at Karolinska Institutet have now discovered a new mechanism of a major risk gene for multiple sclerosis (MS) that triggers disease through so-called epigenetic regulation. They also found a protective genetic variant that reduces the risk for MS through the same mechanism.
Synthetic DNA Shuffling Enzyme Outpaces Natural CounterpartNews
A new synthetic enzyme, crafted from DNA rather than protein, flips lipid molecules within the cell membrane, triggering a signal pathway that could be harnessed to induce cell death in cancer cells. Researchers say their lipid-scrambling DNA enzyme is the first in its class to outperform naturally occurring enzymes – and does so by three orders of magnitudeREAD MORE
Antarctic Worm and Machine Learning Help Identify Cerebral Palsy EarlierNews
A research team has released a study in the peer-reviewed journal BMC Bioinformatics showing that DNA methylation patterns in circulating blood cells can be used to help identify spastic cerebral palsy (CP) patients. The technique which makes use of machine learning, data science and even analysis of Antarctic worms, raises hopes for earlier targeted CP therapies.